In the next five years we are likely to have up to 36 biosimilars to treat rheumatologic diseases – that’s in addition to the biologics we already have. But do we have enough evidence to confidently switch patients between innovator products and their biosimilars? Is there anything to learn from the less complex molecules that ...
Unravelling the complex world of biologics and biosimilars
14 Jun 2016
Sponsored by AbbVie